The clinical part of the project was implemented under the leadership of KPMI Director Marcis Leja in close cooperation with specialists from the Latvian Oncology Center of Riga Eastern Clinical University Hospital and the GASTRO Digestive Diseases Centre. Within the framework of the project, many clinical activities were carried out involving patients and testing of equipment in a clinical conditions.
Before starting work in the clinic, a validation study of portable express analyzers was initially successfully implemented, which helped to evaluate the repeatability and variability between all devices, thus it was possible to start the next stage of the project - "Clinical validation study" with real patients. The study included patients with a confirmed diagnosis of gastric cancer and patients with high-risk changes, as well as control patients with a known condition of the gastric mucosa. The main goal of this project section was to develop a model that would differentiate the studied changes from the control measurements, so that in the future this model could be used for individuals with well-defined gastric changes. A total of 198 patients participated in this study, including 81 gastric cancer patients and 117 subjects from the control group. In parallel, a "Validation study in the general population" was carried out. The research took place in Jekabpils regional GISTAR center. In total, breath samples from 392 participants of the regional GISTAR center were obtained on all three analyzers.
Based on the data obtained in the clinic, a mathematical model was developed and the specificity and sensitivity of 16 different volatile organic compound sensors were evaluated, identifying exhaled air from cancer patients as opposed to exhaled air from healthy people. The specificity of this mathematical model, the parameter induction of which is performed from the measurement data when tested on a new data set, significantly exceeds the performance of any individual sensor parameter. Work on commercialization is currently ongoing.
![](https://www.facebook.com/sharer/sharer.php?app_id=957173808510696&sdk=joey&display=popup&ref=plugin&src=share_button&u=https%3A%2F%2Fwww.lu.lv%2Fpar-mums%2Flu-mediji%2Fzinas%2Fzina%2Ft%2F81146%2F&picture=https%3A%2F%2Fwww.lu.lv%2Ffileadmin%2Fuser_upload%2FLU.LV%2FApaksvietnes%2FIzstrade%2Fkpmi%2F2020%2F4.JPG&description=Today, 28 September, the project of the Institute of Clinical and Preventive Medicine of the University of Latvia "Volatile Marker Breath Analyzer for Gastric Cancer Screening" has been completed. The project is based on the clinical need to introduce a screening method for the early detection of gastric cancer and precancerous changes. The goal of the project is to identify gastric cancer and precancerous conditions using nanosensors that detect volatile organic compounds, as well as to develop a modern portable nanosensor express analyzer for screening gastric cancer and precancerous conditions. The project was implemented over a period of 36 months, starting from September 28, 2018.){kind=link}